Incyte (INCY)
NASDAQ: INCY · Biotechnology · Wilmington, DE
Our rating: Positive
Positive reaffirmed at $120.39, moderate conviction, October 30, 2026.
Breaks if: The Positive call flips Cautious if reported revenue growth comes in below 8% for two consecutive annual periods — at that pace, an 18.8x earnings multiple would be genuinely difficult to justify. On price, a drawdown of 22% or more from today's $120.39 (below roughly $94) within the next twelve months, absent a material positive fundamental development, would indicate the market is pricing in risk not yet visible in the company's reported figures.
Key figures
| Market value | $23.4B |
|---|---|
| Revenue, last 12 months | $6.0B |
| Net income, last 12 months | $403M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | 57.9× |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | 10.4% |
| Return on equity | 7.8% |
| Beta to the S&P 500 | 0.52 |
| Volatility, annualized | 33.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.6B | 14.0% | $-3.86 | n/a |
| June 30, 2026 | $1.7B | 37.7% | $2.81 | n/a |
| March 31, 2026 | $1.3B | 20.9% | $1.47 | n/a |
| December 31, 2025 | $1.5B | 27.8% | $1.46 | n/a |
| September 30, 2025 | $1.4B | 20.0% | $2.11 | n/a |
| June 30, 2025 | $1.2B | 16.5% | $2.04 | n/a |
| March 31, 2025 | $1.1B | 19.5% | $0.80 | n/a |
| December 31, 2024 | $1.2B | 16.3% | $0.95 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.89B: Claude 28%, Gemini 40%, Mistral 35%
- Diluted earnings per share are at least $1.46: Claude 55%, Gemini 20%, Mistral 60%
30 ledger entries and 24 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.